<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740583</url>
  </required_header>
  <id_info>
    <org_study_id>CLPR-007</org_study_id>
    <nct_id>NCT01740583</nct_id>
  </id_info>
  <brief_title>Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation</brief_title>
  <acronym>ALIGN</acronym>
  <official_title>A Feasibility Study of the Mitralign Annuloplasty System for the Treatment of Chronic Functional Mitral Valve Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitralign, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitralign, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and device performance of the Mitralign
      system (&quot;MPAS&quot;) to treat functional mitral valve regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ALIGN study is a single arm, prospective study. The objective of the study is to
      investigate the safety and performance of a catheter-based plication device intended to
      reduce the circumference of the dilated mitral valve. The study will enroll up to 50 subjects
      from up to 5 sites (Paraguay, Columbia, Dominican Republic, Brazil, and India) who will be
      followed for 36 months post index procedure. Enrollment is defined at the time the study
      device is inserted into the body and patients will be followed at 30 days, and Months 6, 12,
      24 and 36 post index procedure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Events (MAE)</measure>
    <time_frame>within 30 days post procedure</time_frame>
    <description>MAE defined as occurrence of any of the following: Mitral valve-related surgery/intervention, myocardial infarction, cardiac tamponade, stroke, device and/or procedure-related death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Outcomes</measure>
    <time_frame>at 6 months</time_frame>
    <description>Freedom from an increase in ventricular diameter</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>annuloplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>percutaneous annuloplasty</intervention_name>
    <description>plication of the mitral valve annulus</description>
    <arm_group_label>annuloplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA II-IV

          -  Structurally normal mitral valve

          -  At least Grade 2 mitral regurgitation

          -  Left ventricular ejection fraction not less than 20% and not greater than 45%

          -  Left ventricular end diastolic diameter not less than 5.0 cm and not greater than 7.5
             cm

        Exclusion Criteria:

          -  Pregnant or lactating female

          -  Mitral stenosis

          -  Mod/severe aortic stenosis or regurgitation

          -  Mod/severe tricuspid stenosis or regurgitation

          -  Endocarditis

          -  Previous mitral valve repair or MV replacement

          -  Bioprosthetic or mechanical aortic valve

          -  Known unstable angina or MI within 30 days prior to procedure

          -  CVA within past 6 months

          -  Known contraindications to blood transfusion, contrast dye, DAPT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Ebner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanatorio Italiano (The Italian Hospital)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica CardioVID</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonio Dager, MD</name>
      <address>
        <city>Valle del Cauca</city>
        <state>Cali</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux Heart University Hospital</name>
      <address>
        <city>Bordeaux-Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Heart of Poland S.A.</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-316</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne HZP</name>
      <address>
        <city>Poznan</city>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytutem Kardiologii</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>France</country>
    <country>Paraguay</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>November 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitral valve, regurgitation, annuloplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

